An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer’s Disease

Manuscript Number: 

19-0864R1

Author(s): 
Stan Chamberlain, John Didsbury, Hoda Gabriel, Warren J. Strittmatter

Disclosures

Stan Chamberlain

  • Equity:
    Stock options and stock grants
    Sponsors:
    Chief Scientific Officer

John Didsbury

  • Equity:
    T3D Therapeutics, Inc. common stock, 11% owner
    Sponsors:
    CEO of T3D Therapeutics, Inc.

Hoda Gabriel

  • Equity:
    stock options as part of compensation
    Sponsors:
    Executive Director of Clinical Development at T3D Therapeutics

Warren J. Strittmatter

  • Equity:
    Stock options from T3D Therapeutics Inc. Present options are approximately 133,000 shares
    Sponsors:
    Chief Medical Officer of T3D Therapeutics Inc.